Zevra Therapeutics, Inc. reported $136M of revenue over the trailing twelve months, +119% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $136M (to Q2 2026). Net income: $58M, trailing twelve months to Q2 2026. Free cash flow: $33M, trailing twelve months to Q2 2026. Operating margin: 57%, trailing twelve months to Q2 2026.

ZVRAZevra Therapeutics, Inc.

Healthcare

$11.00+7.9% 1Y

$11.00

$8.1052 weeks$14.74

ZVRA as reported

Zevra Therapeutics, Inc. reported $136M of revenue over the trailing twelve months, +119% on the year before. 11 reported series are charted on this page, each one as filed.

$136M

Revenue, trailing twelve months · to Q2 2026 · +119% against the twelve months before

Net income: $58M
Net income · +2104% year on year · trailing twelve months to Q2 2026
Free cash flow: $33M
Free cash flow · −170% year on year · trailing twelve months to Q2 2026
Operating margin: 57%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for ZVRA, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$136M	+119%	Q2 2026
Net income	$58M	+2104%	Q2 2026
EPS	$0.92	−500%	Q2 2026
Gross margin	95%	n/a	Q2 2026
Operating margin	57%	n/a	Q2 2026
Net margin	40%	n/a	Q2 2026
ROE	42%	n/a	Q2 2026
ROA	27%	n/a	Q2 2026
ROIC	−141%	n/a	Q2 2026
Free cash flow	$33M	−170%	Q2 2026
P/E	12.0	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.